Individuals with a diagnosis in the psychosis spectrum Mental and Behavioural Disorders
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. A diagnosis in the psychosis spectrum according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition 2. 18 years or older
Exclusion criteria
Exclusion criteria: 1. Severe psychotic symptoms (mean positive symptoms > 5 measured by PANSS) 2. Substance dependence (not substance abuse), verified by Miniscan. 3. Co-morbid neurological disorder, verified by onsite therapist. 4. Co-morbid personality disorder, verified by onsite therapist. 5. Estimated IQ < 70, onsite therapist decides if the patients’ intelligence is sufficient for participation. 6. Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Victimization, measured using the Integrale Veiligheidsmonitor (IVM) and the Conflicts Tactics Scale - revised (CTS2) at baseline (pre), directly after the intervention-period (post) and 6/18/30 months following the intervention. Mediating factors: We expect that the effect of the intervention on victimization is mediated by several risk factors, on which our intervention is based. Mediation factors will be measured at baseline (pre), directly after the intervention-period (post) and at 6 months follow-up. Mediating factors we defined in our study are: 1. Social cognition (Faux Pas task) 2. Aggression regulation (Self-Expression and Control Scale, ZECV) 3. Internalized stigma (Internalized Stigma of Mental Ilness Scale, ISMI) 4.Social behavior (Interpersonal Behavior Scale, SIG) 5. Self-esteem (Self-esteem Rating Scale - Short Form, SERS-SF) 6. Insight (Psychosis Insight Scale, PI) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Quality of live (MANSA) 2. Recovery (National Recovery Scale, NHS) 3. Societal participation (Social Functioning Scale, SFS) 4. Symptoms (Brief Negative Symptom Scale, BNSS) 5. Trauma (Trauma Screening Questionnaire) 6. Physical activation (Pedometer, Yamax EX 510) 7. Endurance (Modified Shuttle Test, MST) Measured at baseline, directly after the intervention and at 6, 18 and then 30 months follow-up. | — |
Countries
Netherlands